Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00177814
Status:
COMPLETED
Last Update Posted:
2018-06-12
First Post:
2005-09-13
Brief Title:
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The proposed endpoints of the study would be comparative use of piperacillin versus broader spectrum agents eg piperacillintazobactam etc measured as defined daily doses per 1000 patient days physician acceptance of piperacillin as part of a streamlining program measured as successful occurrences of the use of piperacillin as streamlining therapy changes in susceptibility patterns of broad spectrum antibiotics measured as Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics and outcome of patients treated with streamlined therapy
Detailed Description:
The following variables will be followed time and location of positive cultures underlying diseases and severity of illness recent immunomodulative therapies physical exam findings laboratory and radiographical data antimicrobial usage microbiological data and resistance patterns choice of antibiotics once organism is identified suspected source of infection bacteriological outcomes laboratory results demographic information medications clinical outcome gender height weight ethnicity and past medical history
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None